Company: HROW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022980
Chunk: 56

Company: HARROW, INC.
Filing Date: 2025-08-11
Form: 10-Q
Item: Item 1
Chunk 56
---
 of customers who have accepted our FRESHKOTE
product as an alternative. We continue to review opportunities to reduce the size of our compounded formulary, improve and simplify our
compounding capabilities, and transition other ImprimisRx customers from compounded formulations to Harrow’s FDA-approved products.

Results
of Operations

The
following period-to-period comparisons of our financial results for the three and six months ended June 30, 2025 and 2024 are not necessarily
indicative of results for any future period.

31

Revenues

Our
revenues include amounts recorded from sales of proprietary compounded formulations, sales of branded products to wholesalers through
a third-party logistics facility, commissions from third parties and revenues received from royalty payments owed to us pursuant to out-license
arrangements.

The
following presents our revenues for the three and six months ended June 30, 2025 and 2024:

    For the
                                                                  Three Months Ended  
       
    For the
                                                                  Six Months Ended  

    June 30,  
       
    June 30,  
    $ 

    2025  
    2024  
    Variance  
    2025  
    2024  
    Variance 
  
    IHEEZO 
    $18,336,000  
    $11,295,000  
    $7,041,000  
    $23,558,000  
    $13,616,000  
    $9,942,000 
  
    VEVYE 
     18,641,000  
     4,315,000  
     14,326,000  
     40,156,000  
     6,912,000  
     33,244,000 
  
    Other branded products 
     5,212,000  
     11,681,000  
     (6,469,000) 
     6,169,000  
     20,553,000  
     (14,384,000)
  
    Other revenues 
     85,000  
     68,000  
     17,000  
     171,000  
     147,000  
     24,000 
  
    Branded revenue, net 
     42,274,000  
     27,359,